Quest Laboratories (NSE:QUESTLAB) PE Ratio without NRI: 56.35 (As of Jun. 26, 2026) — 21% Below Median


NSE:QUESTLAB Quest Laboratories Ltd NSE:QUESTLAB
44 GF Score
Price ₹98.05
! 8 Warning Signs
View Full Analysis

What is Quest Laboratories PE Ratio without NRI?

Quest Laboratories NSE:QUESTLAB -1.56% 44 PE Ratio without NRI is 56.35 as of Jun. 26, 2026, which is 21% below its 10-year median of 71.48. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 8 warning signs investors should review. Among 653 Drug Manufacturers companies, Quest Laboratories ranks worse than 85.3% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-26), Quest Laboratories's share price is ₹98.05. Quest Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.74. Therefore, Quest Laboratories's PE Ratio without NRI for today is 56.35.

During the past 6 years, Quest Laboratories's highest PE Ratio without NRI was 108.98. The lowest was 37.99. And the median was 71.48.

Quest Laboratories's EPS without NRI for the three months ended in Mar. 2026 was ₹1.74. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.74.

As of today (2026-06-26), Quest Laboratories's share price is ₹98.05. Quest Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.74. Therefore, Quest Laboratories's PE Ratio (TTM) for today is 56.35.

Good Sign:

Quest Laboratories Ltd stock PE Ratio (=11.22) is close to 3-year low of 11.22.

During the past years, Quest Laboratories's highest PE Ratio (TTM) was 108.98. The lowest was 37.99. And the median was 71.48.

Quest Laboratories's EPS (Diluted) for the three months ended in Mar. 2026 was ₹1.74. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.74.

Quest Laboratories's EPS (Basic) for the three months ended in Mar. 2026 was ₹1.74. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.74.


Quest Laboratories  (NSE:QUESTLAB) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Quest Laboratories PE Ratio without NRI Related Terms


Quest Laboratories PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Quest Laboratories's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest Laboratories PE Ratio without NRI Chart

Quest Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PE Ratio without NRI
Get a 7-Day Free Trial N/A N/A N/A 12.37 11.40

Quest Laboratories Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Mar25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial N/A N/A N/A 12.37 11.40

NSE:QUESTLAB vs LLY, JNJ, ABBV: PE Ratio without NRI Comparison

For the Drug Manufacturers - General subindustry, Quest Laboratories's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest Laboratories PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Quest Laboratories's PE Ratio without NRI falls into.


NSE:QUESTLAB
44GF Score
Quest Laboratories Ltd NSE:QUESTLAB
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quest Laboratories PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Quest Laboratories's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=98.05/1.740
=56.35

Quest Laboratories's Share Price of today is ₹98.05.
Quest Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1.74.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 56.35 mean?
Quest Laboratories (NSE:QUESTLAB) has a PE Ratio without NRI of 56.35 as of Jun. 26, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Quest Laboratories and its competitors. This is 21% below median its historical median of 71.48. Over the past decade, Quest Laboratories' PE Ratio without NRI has ranged from 37.99 to 108.98. According to the industry distribution chart, Quest Laboratories ranks #557 out of 653 companies in the Drug Manufacturers industry, placing it in the top 85.3%.
Is Quest Laboratories' PE Ratio without NRI too high?
Quest Laboratories' current PE Ratio without NRI of 56.35 is 21% below median its 10-year median of 71.48. Over the past 10 years, this metric has ranged from a low of 37.99 to a high of 108.98. The Drug Manufacturers industry median PE Ratio without NRI is 20.26. Quest Laboratories' value of 56.35 is 178.1% above this industry median. Based on the distribution chart, Quest Laboratories ranks #557 out of 653 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' PE Ratio without NRI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #557 out of 653 companies for PE Ratio without NRI. This places Quest Laboratories in the lower half of its industry. The industry median PE Ratio without NRI is 20.26. Quest Laboratories' value of 56.35 is 178.1% above this benchmark. Historically, Quest Laboratories' own PE Ratio without NRI has ranged from 37.99 to 108.98 over the past decade. While the company's 10-year median is 71.48 vs. the industry median of 20.26, Quest Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 20.26, based on 653 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current PE Ratio without NRI of 56.35 is 178.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 20.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current PE Ratio without NRI is 56.35, which is 21% below median its own 10-year median of 71.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current PE Ratio without NRI of 56.35. The current PE Ratio without NRI is 56.35, which is 21% below median its 10-year median of 71.48 and 178.1% above the Drug Manufacturers industry median of 20.26. Quest Laboratories' overall GF Score™ is 44/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current PE Ratio without NRI is 56.35 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quest Laboratories Business Description

Address Sector III, Plot No. 45, Pithampur Industrial Area, Opposite Kissan Pipe Unit 4, District Dhar, Pithampur, Dhar, MP, IND, 454775
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score

Get the complete analysis for NSE:QUESTLAB

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹98.05
Price